KA/EN
Register
Medicines reference
Search
Search
Active substance

Marbofloxacin

Favourites

Fluoroquinolone. Registered in Georgia: 2 veterinary products. Forms: aerosol / spray, ear drops, scored tablet, solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Marbofloxacin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2 mg/kg Dog, Cat Bacterial Infection; Skin and Soft Tissue Infection By mouth / Subcutaneous once daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Marbocyl P 5 mg Tablet for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
VMD Marbocyl SA SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Marbocyl SA 200 mg powder and solvent for solution for injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
2.75–5.5 mg/kg Dog, Cat Bacterial Infection By mouth once daily
FDA 2019
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Zeniquin (marbofloxacin) Tablets - FDA-approved animal drug label, NADA 141-151
US Food and Drug Administration, via DailyMed, 2019
5.5 mg/kg Dog Skin and Soft Tissue Infection By mouth once daily
ISCAID 2025
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Antimicrobial use guidelines for canine pyoderma by the International Society for Companion Animal Infectious Diseases (ISCAID)
Veterinary Dermatology, 2025
2 mg/kg Dog Skin and Soft Tissue Infection Subcutaneous Single dose
VMD Marbocyl SA SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Marbocyl SA 200 mg powder and solvent for solution for injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in animals hypersensitive to fluoroquinolones or any product component. Do not use where quinolone resistance is confirmed; cross-resistance among fluoroquinolones is almost complete.
    Sources: VMD SPC · VMD · FDA
  • Critical (Dog)
    Age limits differ by product: one label prohibits use in dogs younger than 12 months and in slow-growing large breeds younger than 18 months; another uses 8 months for small/medium breeds, 12 months for large breeds, and 18 months for giant breeds. Fluoroquinolones can erode articular cartilage in growing dogs.
    Sources: VMD SPC · VMD · FDA
  • Critical (Cat)
    Marbofloxacin is contraindicated in cats under 12 months of age
    Sources: VMD SPC · VMD · FDA
  • Warning
    Use with caution in dogs or cats with epilepsy because fluoroquinolones can cause neurological adverse effects. Overdose may cause acute neurological disturbances requiring symptomatic management.
    Sources: VMD SPC · VMD
  • Warning
    Safety in pregnant dogs and cats has not been established. Use only after a benefit-risk assessment. Studies in pregnant rats and rabbits found no adverse effects, but target-species studies are lacking; this means unassessed, not proven safe.
    Sources: VMD SPC · VMD
  • Warning
    Safety during lactation in dogs and cats has not been established. Use only after a benefit-risk assessment; the reviewed labels provide pregnancy data but no separate lactation statement.
    Sources: FDA
  • Warning (Cat)
    The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. retin Ophthalmoscopy revealed no treatment-related eye abnormalities.
    Sources: FDA

Known Drug Interactions

  • Major warning Marbofloxacin + Aminophylline
    Theophylline metabolism is inhibited by... enrofloxacin, and marbofloxacin
    Recommendation: Reduce the aminophylline dose during concomitant use. Signs of toxicity include vomiting, excitation, tachyarrhythmia, and seizures.
    Sources: MSD Vet Manual
  • Major warning Marbofloxacin + Sucralfate
    Sucralfate, antacids, and mineral supplements containing iron, aluminium, calcium, magnesium, zinc, or other divalent or trivalent cations can reduce quinolone absorption and bioavailability. The magnitude is drug-specific; marbofloxacin is covered by a direct product warning.
    Recommendation: Avoid concurrent oral administration. If both medicines are necessary, separate sucralfate or the cation-containing product from the quinolone by at least 2 hours and monitor clinical response.
    Sources: VMD SPC · VMD · FDA · ACVIM · JVIM
  • Major warning Marbofloxacin + Theophylline
    Fluoroquinolones can increase serum theophylline concentrations. When marbofloxacin and theophylline are used together, monitor theophylline closely because its therapeutic range is narrow and toxicity may occur.
    Recommendation: If concomitant use is necessary, monitor serum theophylline and be prepared to reduce its dose. Alternatively, choose another antibiotic.
    Sources: VMD SPC · VMD
Latin name
Marbofloxacin
Georgian name
მარბოფლოქსაცინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
2 of 6 forms
Products
Aristos P, Aurizon, Gefriderm, Marboflex, Marbotis, Otoxolan
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration6

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Aristos P 20 mg, Scored tablet

marbofloxacin 20 mg, quadrisected tablet for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.5/10
Good
vetman assessment

Aristos P

20 mg, marbofloxacin 20 mg, quadrisected tablet for dogs
Assessed clinical scopeDog · Complete dog label: oral treatment of susceptible bacterial skin/soft-tissue, urinary including selected prostatic/epididymal, and respiratory infections when marbofloxacin is a justified reserve choice · By mouth
Care settingOutpatient reserve-antimicrobial treatment after diagnosis and accurate weighing, with susceptibility testing whenever possible and site-specific planned reassessment
vetman score 7.5/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 292-11 · Verified on 22 Oct 2026

A credible, accurately quarter-divisible oral reserve fluoroquinolone for selected susceptible adult-dog infections. Its good score is constrained by stewardship, long potential courses and the unresolved clinical adequacy of the 2 mg/kg label for staphylococcal pyoderma under current 5.5 mg/kg guidance.

Regulatory and scientific credibility9.0/10

The exact 20 mg Fatro product has current transparent EU/Czech and Georgian authorisations, Italian reference-product equivalence and current official GB/FDA same-active controls. Its generic legal basis is not a penalty, but independent exact-product outcome evidence is limited.

Clinical efficacy6.5/10

Marbofloxacin is established and the product has a clear 2 mg/kg regimen across susceptible skin, urinary and respiratory infections. Efficacy remains site/susceptibility dependent, and a material limitation is that current ISCAID pyoderma guidance recommends at least 5.5 mg/kg for Staphylococcus—well above this exact label—while fluoroquinolones remain reserve agents.

Safety and tolerability7.0/10

Correctly selected adult dogs generally tolerate labelled treatment; reported GI/thirst/activity changes are usually rare or very rare and mild. Juvenile cartilage injury, CNS/overdose effects, quinolone cross-resistance, reproductive prohibition and cation-reduced exposure remain clinically important hard boundaries.

Clinical practicality7.5/10

Once-daily home dosing and equal 5 mg quarters provide practical 2.5 kg steps. The broad site-specific courses can run 21-40 days, so adherence, quarter handling, repeated response review and stewardship are substantial; dogs below or between validated steps need a more suitable strength.

Full-course cost-effectiveness-

Current Georgian full-course price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this score covers the complete authorised susceptible bacterial dog scope. It does not cover cats, prophylaxis, non-bacterial disease, every organism without susceptibility, another strength or another jurisdiction's regimen.
  • Stewardship hard stop: marbofloxacin is an EMA AMEG Category B (Restrict) fluoroquinolone. Use only when an effective lower-category option is unsuitable, preferably after culture/susceptibility, and document the reason.
  • Pyoderma dose conflict: exact Aristos P is labelled 2 mg/kg/day, while ISCAID 2025 recommends at least 5.5 mg/kg for Staphylococcus spp. Do not silently increase this product; review isolate/site adequacy and select the appropriate authorised or explicitly justified strategy.
  • Exact dose: 2 mg/kg PO once daily, one 20 mg tablet/10 kg. Equal quarters provide 5 mg and a 2.5 kg step. Weigh accurately; do not invent eighths, crush-derived doses or transfer FDA Zeniquin's 2.75-5.5 mg/kg range.
  • Duration is site-specific, not automatic: skin at least 5 and up to 40 days; urinary at least 10 and up to 28 days; respiratory at least 7 and up to 21 days. Extend only after objective response and diagnosis/source-control review.
  • Do not use in growing dogs younger than the exact breed-size limit of 8-18 months or in sexually immature male dogs: fluoroquinolones can erode juvenile articular cartilage. Do not let apparent tolerance erase the contraindication.
  • Avoid in CNS dysfunction and use extreme caution with seizure risk. Stop and reassess ataxia, seizure, depression, aggression or marked hyperactivity; neurological overdose has no specific antidote and is treated symptomatically.
  • Do not use for confirmed/suspected quinolone resistance or strict anaerobic, yeast or fungal infection. Cross-resistance is extensive; treatment failure requires culture, source-control and diagnosis review—not blind dose escalation.
  • Exact-product pregnancy/lactation use is prohibited in the sourced label. Do not replace that restriction with a comparator brand's different benefit-risk wording or laboratory-species reassurance.
  • Oral aluminium, calcium, magnesium and iron can reduce marbofloxacin bioavailability. Concomitant theophylline can accumulate because fluoroquinolones reduce its clearance; review dose reduction and toxicity monitoring. Wash hands and seek medical advice after accidental ingestion.
Assessment sources
  1. EU SPC 20262026
  2. Aristos P GE register2026
  3. Aristos P IT equivalence2023
  4. Marbocyl P 20 VMD2026
  5. FDA 20192019
  6. EMA AMEG 20252025
  7. ISCAID 20252025
  8. ISCAID urinary 20192019
  9. ISCAID 20172017
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Marbofloxacin20 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
Fatro S.p.A. · Italy
Manufacturer (register)
Fatro S.p.A., Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1206, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: არისტოს პ 20 მგ
№ 292-11
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ 96/057/18-C
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Prescription-only reserve fluoroquinolone. Exact label: 2 mg/kg PO once daily, one 20 mg tablet/10 kg. Skin/soft tissue 5-40 days, urinary 10-28 days and respiratory 7-21 days only according to diagnosis, susceptibility and response. Equal quarters provide 5 mg/2.5 kg steps. Current specialist guidance recommends at least 5.5 mg/kg for staphylococcal pyoderma; do not silently transfer that higher regimen—review whether the exact product/label is adequate or choose another authorised strategy.

Aurizon 3 mg/ml + 10 mg/ml + 0.9 mg/ml, Ear drops

ear drops suspension, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.8/10
Good
vetman assessment

Aurizon

3 mg/ml + 10 mg/ml + 0.9 mg/ml, ear drops suspension, for dogs
Assessed clinical scopeDog · Label-concordant treatment of canine otitis externa caused by marbofloxacin-susceptible bacteria and clotrimazole-susceptible fungi, especially Malassezia pachydermatis, with concurrent control of inflammation · Into the ear
Care settingVeterinary diagnosis and selection after otoscopy and cytology; outpatient administration after cleaning and drying, with day-7 veterinary reassessment and investigation of the underlying cause.
vetman score 7.8/10 Good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A good, evidence-supported once-daily reference option for correctly diagnosed mixed bacterial/fungal canine otitis externa. Its fluoroquinolone component prevents routine first-line use: confirm an intact tympanum, base selection on cytology and susceptibility context, and investigate the underlying disease.

Regulatory and scientific credibility9.0/10

Aurizon is the long-established reference product with current exact EU/EEA and GB veterinary authorisations, a current regulator-hosted SPC, post-authorisation history and direct comparative trials. It is not registered in the checked Georgian or US registers.

Clinical efficacy7.5/10

A 140-dog phase III comparison found the marbofloxacin/clotrimazole/dexamethasone suspension equivalent to an established comparator, with a 58.3% cure rate and advantages in pain, discharge, odour and day-14 assessment. A bilateral Malassezia study also found greater improvement in yeast count, erythema, cerumen and pruritus than antifungal monotherapy. Benefit depends on matching cytology/pathogen susceptibility and addressing the primary cause.

Safety and tolerability7.0/10

Topical exposure is much lower than systemic treatment, but the intact tympanic membrane must be confirmed. Rare mostly transient deafness, local irritation and corticosteroid-related skin thinning, delayed healing, laboratory changes or adrenal suppression are possible; avoid pregnancy/lactation and unnecessary use in growing dogs.

Clinical practicality7.5/10

Ten drops once daily for 7-14 days is simpler than twice-daily alternatives, and the current packs provide one cannula per intended patient. The ear must still be examined, cleaned and dried, the suspension shaken and massaged in, and continuation beyond day 7 requires veterinary reassessment; in-use shelf life is two months.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Perform otoscopy and verify an intact tympanic membrane before every course. Do not use with a perforated or unvisualised tympanum; stop and reassess urgently for head tilt, nystagmus, ataxia, hearing change or other vestibular signs.
  • Cytology is required in every otitis externa case and should be repeated at recheck. Sample before cleaning; identify and manage allergy, foreign body, parasites, conformation, endocrine disease, otitis media or another primary/perpetuating cause rather than repeatedly suppressing secondary infection.
  • Marbofloxacin is an EMA AMEG Category B fluoroquinolone. Do not use this combination prophylactically or as a routine first choice; use a lower-category topical option when likely effective and document why a fluoroquinolone is required. Culture and susceptibility are especially important with rods, chronic/recurrent disease or poor response.
  • Do not use when resistance to marbofloxacin or clotrimazole is known, or with hypersensitivity to fluoroquinolones, azole antifungals, corticosteroids or excipients. Failure despite correct administration requires diagnosis and susceptibility review, not automatic repetition or prolongation.
  • Avoid use in young growing dogs unless the exceptional need clearly outweighs the risk. Quinolones are associated with weight-bearing cartilage injury and arthropathy in immature animals.
  • Do not use during pregnancy or lactation. Record reproductive status before treatment and choose a suitable alternative for pregnant, breeding or nursing animals.
  • Clean and dry the external canal before dosing, shake the suspension as directed, instil exactly ten drops once daily and massage the ear base gently. Reassess at day 7 before extending to 14 days; use a separate cannula/dropper for each dog and do not continue beyond the labelled course.
  • Rare, usually transient deafness is reported, mainly in older dogs. Establish baseline hearing and neurologic status when relevant; stop and reassess promptly for reduced hearing, pain, marked erythema, vestibular signs or worsening discharge.
  • Prolonged or intensive topical corticosteroid exposure can cause skin thinning, delayed healing, biochemical/haematological changes and adrenal suppression. Avoid duplicate otic/systemic corticosteroids without review and investigate persistent inflammation rather than extending treatment.
  • Avoid skin and eye contact, wash hands after administration and keep the applicator uncontaminated. People hypersensitive to fluoroquinolones, azole antifungals or corticosteroids should avoid handling; seek medical advice after accidental ingestion or persistent exposure symptoms.
Assessment sources
  1. VMD SPC 20252025
  2. Aurizon VMD assessment history2026
  3. Canine otitis phase III comparison2005
  4. Canine Malassezia otitis comparison2006
  5. AIDAP canine otitis guideline2022
  6. AAHA allergic otitis guideline2023
  7. Recurrent canine otitis review2023
  8. EMA AMEG fluoroquinolone category2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Marbofloxacin3 mg/ml Clotrimazole10 mg/ml Dexamethasone0.9 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Vetoquinol · France
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Gefriderm, Aerosol / spray

cutaneous spray solution, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.3/10
Good
vetman assessment

Gefriderm

cutaneous spray solution, for dogs
Assessed clinical scopeDog · Label-concordant treatment of a proved focal acute superficial mixed infection in dogs: marbofloxacin-susceptible Pseudomonas aeruginosa or Staphylococcus pseudintermedius plus ketoconazole-susceptible Malassezia pachydermatis · On the skin
Care settingVeterinarian-directed clinic/home treatment after cytology, organism identification and susceptibility testing, with lesion preparation, exposure control and day-7/day-14 reassessment.
vetman score 7.3/10 Good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A well-documented licensed option for a narrow, proved focal mixed bacterial-and-Malassezia dermatitis. Its value disappears when used empirically, on diffuse/deep disease, or where an antiseptic or narrower agent is suitable.

Regulatory and scientific credibility8.0/10

Current exact UK and EU regulator records provide full composition, authorisation, dose, target-animal PK and safety, while the exact EU public assessment report exposes the pivotal efficacy review; national EU authorisations are traceable, but Georgia and the US have no exact authorisation and no independent published exact-product trial was located.

Clinical efficacy7.5/10

The regulator-reviewed exact-product GCP field trial included 56 eligible dogs, confirmed mixed infections, an active comparator and demonstrated non-inferiority with clinical cure by day 14. This supports efficacy within the narrow proved mixed-infection scope, while antiseptic-first guidance, category-B fluoroquinolone stewardship and the absence of an independent published trial limit broader value.

Safety and tolerability6.5/10

Very rare mild erythema, very low one-zone plasma exposure and a five-times one-zone tolerance study are reassuring, but multi-zone overdose was not studied and steroid-related delayed healing, epidermal thinning/adrenal suppression, reproductive risk, licking and handler inhalation/contact risks remain material.

Clinical practicality7.0/10

A metered spray is practical for focal painful or folded skin and the twice-daily 7-day plan is clear, but clipping/cleaning, 25 cm² measurement, four-zone ceiling, gloves, ventilation, lick prevention, no bathing and 20-minute child/contact restriction add substantial workflow.

Full-course cost-effectiveness-

No verified current Georgian patient-adjusted full-course price is available, so cost is excluded.

Important safety and use flags

  • Veterinary prescription medicine authorised for dogs in GB and EU national markets. Exact-product registers dated 2026-10-15 record it as not authorised in Georgia and the US; this does not negate the GB/EU dossier.
  • Use only when cytology and organism identification show a focal mixed infection: susceptible Pseudomonas or Staphylococcus plus susceptible Malassezia. Do not use for empiric, bacterial-only, yeast-only, diffuse, deep, sterile or noninfectious disease.
  • Marbofloxacin is an EMA category B Restrict fluoroquinolone. Prefer a suitable antiseptic or narrower option; use culture/susceptibility, avoid quinolone-resistant isolates and stop unnecessary components as soon as the mixed indication no longer exists.
  • Clean, clip and remove exudate/debris before dosing. Treat two sprays per 25 cm² twice daily; split larger lesions into measured zones and never exceed four zones simultaneously.
  • Treat seven days and reassess. Continue only if still indicated, never beyond 14 days; persistent infection after day 14 requires diagnosis and a different appropriate product, not automatic extension.
  • Avoid eyes, mucosa, open lesions and wounds. Prevent self- and cross-licking, separate treated dogs when needed, keep hair short and do not bathe or shampoo during administration.
  • Not recommended in pregnancy or lactation; safety is unestablished and ketoconazole was teratogenic/embryotoxic in laboratory animals. Avoid known hypersensitivity to any active or excipient.
  • Prolonged or intensive topical prednisolone can thin epidermis, delay healing and suppress adrenal function. Monitor erythema, irritation, delayed repair and systemic glucocorticoid signs, especially with multiple zones or comorbidity.
  • Avoid concurrent low-pH products because they may inhibit marbofloxacin. No interaction studies establish combined-product safety or efficacy; review every topical/systemic antimicrobial, antifungal and corticosteroid.
  • Handler safety: wear single-use impermeable gloves, spray outdoors or with good ventilation, avoid inhalation/skin/eye contact and flames, and do not let children touch the dog until dry for at least 20 minutes. Pregnant people or those trying to conceive must not administer it.
Assessment sources
  1. Gefriderm UK SPC2026
  2. Gefriderm VMD record2026
  3. Gefriderm EU record2026
  4. Gefriderm EU PuAR2020
  5. ISCAID canine pyoderma 20252025
  6. MSD pyoderma2025
  7. EMA AMEG category B2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Marbofloxacin1.025 mg/ml Ketoconazole2.041 mg/ml Prednisolone0.926 mg/ml
Formulation Type
Aerosol / spray
Administration route
On the skin
Manufacturer
ALPHAVET Zrt. · Hungary
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 22 Oct 2026
 UK Yes, veterinary
№ Vm 51645/4000
Verified on: 22 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Clean/clip and remove exudate/debris; shake and hold 10 cm away. Apply two sprays per 25 cm² twice daily for seven days. If unresolved at day 7, continue only to day 14. Divide larger lesions into 25 cm² zones; maximum four zones simultaneously. Re-evaluate and change treatment if infection persists after 14 days.

Marboflex 10%, Solution

100 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed parenteral treatment of a culture-confirmed marbofloxacin-susceptible bacterial infection in a dog using exact Teknovet Marboflex 10%
Not rateable
No numerical score assigned
vetman assessment

Marboflex

10%, 100 mg/ml, solution for injection
Assessed clinical scopeDog · Proposed parenteral treatment of a culture-confirmed marbofloxacin-susceptible bacterial infection in a dog using exact Teknovet Marboflex 10% · IM,SC,IV
Care settingOff-label calculator: 2 mg/kg SC from an injectable marbofloxacin comparator (0.02 ml/kg here); no exact-product formulation, PK or safety bridge
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, veterinary · № 002568, 002610 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical score cannot responsibly be assigned for dogs. Exact Marboflex 10% is transparently identified and registered in Georgia, but its current manufacturer information is cattle-only and the Georgian authorisation is restricted to cattle, horses, sheep and goats—not companion animals. It is a 100 mg/ml ready solution containing 10 mg/ml benzyl alcohol. The current authorised dog/cat injectable comparator, Marbocyl SA, is a different powder-and-solvent product reconstituted to 10 mg/ml with different excipients and species-specific regimens; current EU 100 mg/ml comparators are likewise food-animal products. No exact-product dog/cat label dose, dilution protocol, bioequivalence/PK bridge, target-animal safety study or clinical outcome evidence was found. The owner-approved prescription workflow can calculate the comparator’s 2 mg/kg SC dose as 0.02 ml/kg for this concentration, but that arithmetic does not establish this presentation’s benefit-risk or validate an improvised dilution.

Marbofloxacin has established authorised injectable dog/cat dosing. In the prescribing workflow Marboflex 10% therefore calculates 2 mg/kg SC as 0.02 ml/kg at 100 mg/ml, explicitly off-label. The exact cattle product still lacks a dog/cat formulation bridge; use accurate low-volume delivery and never substitute its bovine IM regimen.

Important safety and use flags

  • Exact-product boundary: Teknovet Marboflex 10% is a 100 mg/ml cattle product. Its current label does not authorise dogs or cats and supplies no companion-animal dose, dilution method or treatment course.
  • Prescription-workflow exception: calculate the authorised injectable marbofloxacin comparator dose of 2 mg/kg SC as 0.02 ml/kg at this 100 mg/ml strength. This is explicitly off-label and does not establish bioequivalence, PK or target-animal safety for Marboflex 10%.
  • Dose-delivery warning: 2 mg/kg requires only 0.08 ml in a 4 kg patient. Verify syringe accuracy and the final volume independently; do not improvise dilution or use the cattle IM regimen as a dog/cat schedule.
  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use empirically or as routine first choice; obtain culture and susceptibility whenever feasible and document why a lower-category antimicrobial is unsuitable.
  • Do not use for organisms resistant to quinolones or when susceptibility and the infection site do not support marbofloxacin. Cross-resistance is extensive; failure calls for diagnosis, source-control and antibiogram review, not automatic escalation.
  • Avoid in growing animals until skeletal maturity because fluoroquinolones can damage weight-bearing articular cartilage. Age limits from authorised dog/cat products cannot be borrowed as a Marboflex 10% label.
  • Fluoroquinolones can cause neurologic excitation and seizures; use particular caution in dogs with seizure disorders. Exact Marboflex 10% target-animal neurologic safety and overdose margin are not established.
  • The exact cattle information cautions against use with hepatic or renal insufficiency, dehydration and hypersensitivity and reports possible injection-site inflammation. These cattle warnings do not establish frequency, severity or therapeutic margin in dogs or cats.
  • Dog/cat pregnancy, lactation and breeding safety for exact Marboflex 10% are not established. Do not infer safety from bovine use or from reproductive studies of another formulation.
  • Review the full medication plan: fluoroquinolones may raise theophylline exposure; the exact manufacturer information also warns about interactions with coumarins, methylxanthines, NSAIDs and probenecid. Avoid unvalidated syringe mixtures or improvised dilution.
Assessment sources
  1. Teknovet Marboflex 10%2026
  2. Marboflex 10% GE register2026
  3. EU UPD Marbocyl 100 mg/ml2026
  4. VMD Marbocyl SA SPC2025
  5. FDA 20192019
  6. ISCAID 20252025
  7. EMA AMEG 20252025
  8. MSD Vet Manual 20262026
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed parenteral treatment of a culture-confirmed marbofloxacin-susceptible bacterial infection in a cat using exact Teknovet Marboflex 10%
Not rateable
No numerical score assigned
vetman assessment

Marboflex

10%, 100 mg/ml, solution for injection
Assessed clinical scopeCat · Proposed parenteral treatment of a culture-confirmed marbofloxacin-susceptible bacterial infection in a cat using exact Teknovet Marboflex 10% · IM,SC,IV
Care settingOff-label calculator: 2 mg/kg SC from an injectable marbofloxacin comparator (0.02 ml/kg here); no exact-product formulation, PK or safety bridge
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, veterinary · № 002568, 002610 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical score cannot responsibly be assigned for cats. Exact Marboflex 10% is transparently identified and registered in Georgia, but its current manufacturer information is cattle-only and the Georgian authorisation is restricted to cattle, horses, sheep and goats—not companion animals. It is a 100 mg/ml ready solution containing 10 mg/ml benzyl alcohol. The current authorised dog/cat injectable comparator, Marbocyl SA, is a different powder-and-solvent product reconstituted to 10 mg/ml with different excipients and species-specific regimens; current EU 100 mg/ml comparators are likewise food-animal products. No exact-product dog/cat label dose, dilution protocol, bioequivalence/PK bridge, target-animal safety study or clinical outcome evidence was found. The owner-approved prescription workflow can calculate the comparator’s 2 mg/kg SC dose as 0.02 ml/kg for this concentration, but that arithmetic does not establish this presentation’s benefit-risk or validate an improvised dilution.

Marbofloxacin has established authorised injectable dog/cat dosing. In the prescribing workflow Marboflex 10% therefore calculates 2 mg/kg SC as 0.02 ml/kg at 100 mg/ml, explicitly off-label. The exact cattle product still lacks a dog/cat formulation bridge; use accurate low-volume delivery and never substitute its bovine IM regimen.

Important safety and use flags

  • Exact-product boundary: Teknovet Marboflex 10% is a 100 mg/ml cattle product. Its current label does not authorise dogs or cats and supplies no companion-animal dose, dilution method or treatment course.
  • Prescription-workflow exception: calculate the authorised injectable marbofloxacin comparator dose of 2 mg/kg SC as 0.02 ml/kg at this 100 mg/ml strength. This is explicitly off-label and does not establish bioequivalence, PK or target-animal safety for Marboflex 10%.
  • Dose-delivery warning: 2 mg/kg requires only 0.08 ml in a 4 kg patient. Verify syringe accuracy and the final volume independently; do not improvise dilution or use the cattle IM regimen as a dog/cat schedule.
  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use empirically or as routine first choice; obtain culture and susceptibility whenever feasible and document why a lower-category antimicrobial is unsuitable.
  • Do not use for organisms resistant to quinolones or when susceptibility and the infection site do not support marbofloxacin. Cross-resistance is extensive; failure calls for diagnosis, source-control and antibiogram review, not automatic escalation.
  • Avoid in growing animals until skeletal maturity because fluoroquinolones can damage weight-bearing articular cartilage. Age limits from authorised dog/cat products cannot be borrowed as a Marboflex 10% label.
  • Cats carry a fluoroquinolone class warning for retinal toxicity. Marbofloxacin appears less retinotoxic than enrofloxacin, but no Marboflex 10% feline ocular-safety or overdose study exists; visual change, mydriasis or disorientation requires immediate reassessment.
  • The exact cattle information cautions against use with hepatic or renal insufficiency, dehydration and hypersensitivity and reports possible injection-site inflammation. These cattle warnings do not establish frequency, severity or therapeutic margin in dogs or cats.
  • Dog/cat pregnancy, lactation and breeding safety for exact Marboflex 10% are not established. Do not infer safety from bovine use or from reproductive studies of another formulation.
  • Review the full medication plan: fluoroquinolones may raise theophylline exposure; the exact manufacturer information also warns about interactions with coumarins, methylxanthines, NSAIDs and probenecid. Avoid unvalidated syringe mixtures or improvised dilution.
Assessment sources
  1. Teknovet Marboflex 10%2026
  2. Marboflex 10% GE register2026
  3. EU UPD Marbocyl 100 mg/ml2026
  4. VMD Marbocyl SA SPC2025
  5. FDA 20192019
  6. ISCAID 20252025
  7. EMA AMEG 20252025
  8. MSD Vet Manual 20262026
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Marbofloxacin100 mg/ml
Formulation Type
Solution
Administration route
Intramuscular, Subcutaneous, Intravenous
Manufacturer
Teknovet · Türkiye
Registration
Georgia Yes, veterinary
In force until 22 Nov 2026
Veterinary (National Food Agency)
In the register: მარბოფლექსი® 10%
№ 002568, 002610
Verified on: 15 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified The exact label is cattle-only. For the owner-approved dog/cat prescribing workflow, the calculator uses the authorised injectable marbofloxacin comparator dose of 2 mg/kg SC, which equals 0.02 ml/kg at 100 mg/ml (0.08 ml for 4 kg). This is an off-label ingredient-level calculation, not a Marboflex dog/cat label claim; do not use the bovine IM regimen and do not improvise a dilution.

Marbotis 3 mg/ml + 10 mg/ml + 1 mg/ml, Ear drops

ear drops suspension, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.5/10
Good
vetman assessment

Marbotis

3 mg/ml + 10 mg/ml + 1 mg/ml, ear drops suspension, for dogs
Assessed clinical scopeDog · Label-concordant treatment of canine otitis externa caused by marbofloxacin-susceptible bacteria and clotrimazole-susceptible fungi, especially Malassezia pachydermatis, with concurrent control of inflammation · Into the ear
Care settingVeterinary diagnosis and selection after otoscopy and cytology; outpatient administration after cleaning and drying, with day-7 veterinary reassessment and investigation of the underlying cause.
vetman score 7.5/10 Good
Evidence confidence: Medium Georgia: No · Verified on 15 Oct 2026

A good authorised generic-hybrid option with regulator-accepted reference equivalence and favourable handling life, but without an independent exact-product outcome trial. Cytology, intact tympanum, antimicrobial stewardship and day-7 reassessment remain essential.

Regulatory and scientific credibility8.5/10

Marbotis has current exact EU/EEA and GB veterinary authorisations, a 2024 regulator-hosted SPC and a public generic-hybrid assessment establishing reference-product equivalence and favourable benefit-risk. It is not registered in the checked Georgian or US registers.

Clinical efficacy7.0/10

The regulator accepted equivalent efficacy claims to Aurizon from matching composition and physicochemical characteristics; the reference combination has comparative canine evidence for bacterial/fungal otitis and Malassezia-associated inflammation. There is no independent exact-product outcome trial, and success still depends on cytology, susceptibility where indicated and control of the underlying cause.

Safety and tolerability7.0/10

Topical exposure is much lower than systemic treatment, but the intact tympanic membrane must be confirmed. Rare mostly transient deafness, local irritation and corticosteroid-related skin thinning, delayed healing, laboratory changes or adrenal suppression are possible; avoid pregnancy/lactation and unnecessary use in growing dogs.

Clinical practicality7.5/10

Ten drops once daily for 7-14 days is manageable and the six-month in-use shelf life limits waste. The ear still requires examination, meticulous cleaning/drying, shaking, dropper filling and massage, and extending beyond day 7 requires veterinary reassessment.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Perform otoscopy and verify an intact tympanic membrane before every course. Do not use with a perforated or unvisualised tympanum; stop and reassess urgently for head tilt, nystagmus, ataxia, hearing change or other vestibular signs.
  • Cytology is required in every otitis externa case and should be repeated at recheck. Sample before cleaning; identify and manage allergy, foreign body, parasites, conformation, endocrine disease, otitis media or another primary/perpetuating cause rather than repeatedly suppressing secondary infection.
  • Marbofloxacin is an EMA AMEG Category B fluoroquinolone. Do not use this combination prophylactically or as a routine first choice; use a lower-category topical option when likely effective and document why a fluoroquinolone is required. Culture and susceptibility are especially important with rods, chronic/recurrent disease or poor response.
  • Do not use when resistance to marbofloxacin or clotrimazole is known, or with hypersensitivity to fluoroquinolones, azole antifungals, corticosteroids or excipients. Failure despite correct administration requires diagnosis and susceptibility review, not automatic repetition or prolongation.
  • Avoid use in young growing dogs unless the exceptional need clearly outweighs the risk. Quinolones are associated with weight-bearing cartilage injury and arthropathy in immature animals.
  • Do not use during pregnancy or lactation. Record reproductive status before treatment and choose a suitable alternative for pregnant, breeding or nursing animals.
  • Clean and dry the external canal before dosing, shake the suspension as directed, instil exactly ten drops once daily and massage the ear base gently. Reassess at day 7 before extending to 14 days; use a separate cannula/dropper for each dog and do not continue beyond the labelled course.
  • Rare, usually transient deafness is reported, mainly in older dogs. Establish baseline hearing and neurologic status when relevant; stop and reassess promptly for reduced hearing, pain, marked erythema, vestibular signs or worsening discharge.
  • Prolonged or intensive topical corticosteroid exposure can cause skin thinning, delayed healing, biochemical/haematological changes and adrenal suppression. Avoid duplicate otic/systemic corticosteroids without review and investigate persistent inflammation rather than extending treatment.
  • Avoid skin and eye contact, wash hands after administration and keep the applicator uncontaminated. People hypersensitive to fluoroquinolones, azole antifungals or corticosteroids should avoid handling; seek medical advice after accidental ingestion or persistent exposure symptoms.
Assessment sources
  1. VMD SPC 20242024
  2. Marbotis VMD assessment2024
  3. Canine otitis phase III comparison2005
  4. Canine Malassezia otitis comparison2006
  5. AIDAP canine otitis guideline2022
  6. AAHA allergic otitis guideline2023
  7. Recurrent canine otitis review2023
  8. EMA AMEG fluoroquinolone category2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Marbofloxacin3 mg/ml Clotrimazole10 mg/ml Dexamethasone0.9 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Vet-Agro · Poland
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Otoxolan 3 mg/ml + 10 mg/ml + 1 mg/ml, Ear drops

ear drops suspension, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.4/10
Good
vetman assessment

Otoxolan

3 mg/ml + 10 mg/ml + 1 mg/ml, ear drops suspension, for dogs
Assessed clinical scopeDog · Label-concordant treatment of canine otitis externa caused by marbofloxacin-susceptible bacteria and clotrimazole-susceptible fungi, especially Malassezia pachydermatis, with concurrent control of inflammation · Into the ear
Care settingVeterinary diagnosis and selection after otoscopy and cytology; outpatient administration after cleaning and drying, with day-7 veterinary reassessment and investigation of the underlying cause.
vetman score 7.4/10 Good
Evidence confidence: Medium Georgia: No · Verified on 15 Oct 2026

A good authorised generic option with regulator-accepted equivalence to Aurizon, but without an independent exact-product outcome trial. Use only after otoscopy and cytology, reserve the fluoroquinolone appropriately and reassess before extending beyond seven days.

Regulatory and scientific credibility8.5/10

Otoxolan has current exact EU/EEA and GB veterinary authorisations, regulator-hosted product information and a public generic dossier accepting qualitative and physicochemical equivalence to Aurizon. It is not registered in the checked Georgian or US registers.

Clinical efficacy7.0/10

The regulator accepted equivalent efficacy claims to Aurizon from matching composition and physicochemical characteristics; the reference combination has comparative canine evidence for bacterial/fungal otitis and Malassezia-associated inflammation. There is no independent exact-product outcome trial, and success still depends on cytology, susceptibility where indicated and control of the underlying cause.

Safety and tolerability7.0/10

Topical exposure is much lower than systemic treatment, but the intact tympanic membrane must be confirmed. Rare mostly transient deafness, local irritation and corticosteroid-related skin thinning, delayed healing, laboratory changes or adrenal suppression are possible; avoid pregnancy/lactation and unnecessary use in growing dogs.

Clinical practicality7.0/10

Ten drops once daily for 7-14 days is manageable, but the viscous suspension requires 30 seconds of shaking, dropper filling, a separate dropper per dog, prior cleaning/drying and veterinary reassessment at day 7. The fixed ten-drop dose and three-month in-use shelf life are practical but not long-acting.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Perform otoscopy and verify an intact tympanic membrane before every course. Do not use with a perforated or unvisualised tympanum; stop and reassess urgently for head tilt, nystagmus, ataxia, hearing change or other vestibular signs.
  • Cytology is required in every otitis externa case and should be repeated at recheck. Sample before cleaning; identify and manage allergy, foreign body, parasites, conformation, endocrine disease, otitis media or another primary/perpetuating cause rather than repeatedly suppressing secondary infection.
  • Marbofloxacin is an EMA AMEG Category B fluoroquinolone. Do not use this combination prophylactically or as a routine first choice; use a lower-category topical option when likely effective and document why a fluoroquinolone is required. Culture and susceptibility are especially important with rods, chronic/recurrent disease or poor response.
  • Do not use when resistance to marbofloxacin or clotrimazole is known, or with hypersensitivity to fluoroquinolones, azole antifungals, corticosteroids or excipients. Failure despite correct administration requires diagnosis and susceptibility review, not automatic repetition or prolongation.
  • Avoid use in young growing dogs unless the exceptional need clearly outweighs the risk. Quinolones are associated with weight-bearing cartilage injury and arthropathy in immature animals.
  • Do not use during pregnancy or lactation. Record reproductive status before treatment and choose a suitable alternative for pregnant, breeding or nursing animals.
  • Clean and dry the external canal before dosing, shake the suspension as directed, instil exactly ten drops once daily and massage the ear base gently. Reassess at day 7 before extending to 14 days; use a separate cannula/dropper for each dog and do not continue beyond the labelled course.
  • Rare, usually transient deafness is reported, mainly in older dogs. Establish baseline hearing and neurologic status when relevant; stop and reassess promptly for reduced hearing, pain, marked erythema, vestibular signs or worsening discharge.
  • Prolonged or intensive topical corticosteroid exposure can cause skin thinning, delayed healing, biochemical/haematological changes and adrenal suppression. Avoid duplicate otic/systemic corticosteroids without review and investigate persistent inflammation rather than extending treatment.
  • Avoid skin and eye contact, wash hands after administration and keep the applicator uncontaminated. People hypersensitive to fluoroquinolones, azole antifungals or corticosteroids should avoid handling; seek medical advice after accidental ingestion or persistent exposure symptoms.
Assessment sources
  1. VMD SPC 20242024
  2. Otoxolan VMD assessment2016
  3. Canine otitis phase III comparison2005
  4. Canine Malassezia otitis comparison2006
  5. AIDAP canine otitis guideline2022
  6. AAHA allergic otitis guideline2023
  7. Recurrent canine otitis review2023
  8. EMA AMEG fluoroquinolone category2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Marbofloxacin3 mg/ml Clotrimazole10 mg/ml Dexamethasone0.9 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Krka · Slovenia
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗